Box News

Inositol hexaphosphate (IP6), also called phytic acid or “phytate” when in salt form, is a naturally occurring compound found mainly in bran, seeds, legumes and other high-fiber plant foods. In the body it acts as a multitasker: chemically it’s a strong phosphate-rich molecule that can bind metal ions, and biologically it participates in cell signaling and the regulation of growth and stress responses. Those basic properties explain most of the reported health effects. (MDPI)

One frequently described mechanism is antioxidant activity. IP6 can scavenge reactive oxygen species and reduce oxidative damage inside cells, either directly or by helping iron remain in a less reactive form so it does not catalyze harmful free-radical chemistry. By lowering oxidative stress, IP6 can protect tissues from injury in experimental models. (PMC)

A large body of preclinical research (cell culture and animal studies) shows that IP6 influences fundamental processes of cell life: it can slow abnormal cell proliferation, encourage damaged cells to die when appropriate (apoptosis), promote differentiation toward normal cell behavior, and interfere with pathways cancer cells use to survive and spread. These actions, together with immune-modulating effects seen in animals, underlie the interest in IP6 as a chemopreventive and adjunctive agent in cancer research. Animal experiments have repeatedly reported reduced tumor growth and metastasis in several models after IP6 treatment. However, most of this evidence is preclinical—promising but not definitive for routine human use. (PMC)

Beyond cancer models, IP6 has shown beneficial effects in other areas in laboratory and animal studies. Investigators have reported protective effects on organs exposed to toxic drugs, support for intestinal health and barrier function, and signals that IP6 may reduce inflammation and help maintain metabolic and cardiovascular health. Some recent reviews and animal studies also suggest neuroprotective potential (for example in models of Parkinson’s disease), though human data remain sparse. (Nature)

It is important to balance potential benefits with realistic limits and safety considerations. Because IP6 readily binds minerals such as iron, zinc and calcium, high intake from purified supplements or diets very high in phytate can reduce absorption of those trace minerals and, in susceptible populations, contribute to deficiencies. This “antinutrient” behavior is well documented and is the main safety concern for long-term high dosing. Regulatory and nutrition bodies have examined these effects and recommend caution, especially where diets lack diversity or where mineral status is already borderline. (PubMed)

Finally, what does this mean for people? IP6 is biologically active and has a plausible set of mechanisms—antioxidant, metal-binding, cell-signaling modulation—that explain why it produces protective effects in lab and animal studies. Some small human studies and long-term observational data hint at lower cancer rates where diets are rich in whole grains and legumes (the foods that deliver IP6), but large, high-quality clinical trials demonstrating clear, reproducible health benefits of purified IP6 supplements in humans are still limited. For now, the safest, evidence-based approach is to get IP6 as part of a balanced, fiber-rich diet (whole grains, legumes, seeds) rather than high-dose isolated supplements, and to consult a clinician before starting supplements—especially for people who are pregnant, have mineral-absorption issues, or are taking medications. (MDPI)

In short, IP6 is a biologically active plant compound with antioxidant, immune-modulating and cell-regulatory effects that produce convincing protective results in preclinical studies; these findings are promising but not yet strong enough to recommend routine high-dose supplementation for disease prevention without medical guidance.

(Source : ChatGPT)

Une étude a exploré le lien entre l'inflammation chronique, le système immunitaire et le développement du cancer, notamment dans les intestins. Les chercheurs ont identifié un mécanisme par lequel certaines cellules immunitaires, en particulier un sous-type de lymphocytes TH17, peuvent contribuer à la formation du cancer, bien que ce processus puisse être inhibé par des molécules produites par les cellules épithéliales. Cette découverte soulève des questions sur l'usage prolongé des immunothérapies qui stimulent ces lymphocytes et ouvre la voie à de nouvelles thérapies préventives ciblant ce sous-type pour réduire le risque de cancer.

Près d'un cancer sur trois se développe à la suite d'une inflammation chronique, dont l'origine reste incomprise. Dans une nouvelle étude, des chercheurs et chercheuses de l'Inserm, du CNRS, de l'université Claude-Bernard Lyon 1 et du Centre Léon Bérard au Centre de recherche en cancérologie de Lyon[1], ont identifié des lymphocytes impliqués dans les processus inflammatoires et qui seraient en cause dans la génération de ces cancers. Ce travail ouvre de nouvelles perspectives thérapeutiques et de prévention. Les résultats sont publiés dans la revue Nature Immunology.

Comprendre l'origine de la maladie

Environ 30 % des cancers apparaissent à la suite d'une inflammation chronique localisée. C'est notamment le cas de certains cancers colorectaux, de l'intestin grêle, du foie ou encore du pancréas. De nombreuses questions demeuraient toutefois en suspens pour mieux comprendre le développement de ces cancers. Une ou plusieurs cellules immunitaires sont-elles à l'origine du processus inflammatoire conduisant aux cancers ? Si oui, de quelles cellules s'agit-il ?

Répondre à ces interrogations est l'un des objectifs de Julien Marie[2], directeur de recherche à l'Inserm, et de son équipe au Centre de recherche en cancérologie de Lyon (Inserm/CNRS/Université Claude-Bernard Lyon 1/Centre Léon Bérard) afin de mieux comprendre la manière dont la maladie est initiée.

Les chercheurs et chercheuses se sont intéressés tout particulièrement à une population de cellules immunitaires, les lymphocytes TH17, qui sont déjà connus pour être impliqués dans de nombreuses maladies inflammatoires, comme la sclérose en plaques ou encore la maladie de Crohn.
Ces cellules qui contribuent au développement de cancers

L'hypothèse était que les lymphocytes TH17 ne constituent pas une population homogène, mais qu'ils peuvent en fait être divisés en plusieurs sous-groupes. En utilisant des approches dites de « séquençage de l'ARN à cellule unique », les scientifiques ont démontré cette hétérogénéité des cellules TH17 au sein de l'intestin.

« Plus précisément, dans cette étude, nous montrons pour la première fois qu'il existe en fait huit sous-types de lymphocytes TH17 ayant des rôles distincts. L'un d'entre eux a un rôle tumorigénique, c'est-à-dire que lorsque certains freins d'activation sont levés, il va contribuer au développement de cancers. Au contact de ces cellules TH17, les cellules de l'intestin qui étaient pourtant saines jusqu'ici vont devenir cancéreuses », explique Julien Marie.

Les scientifiques ont ensuite montré que cette population tumorigénique est accrue chez des patients à fort risque de cancer. Enfin, ils ont aussi identifié qu'une protéine, la cytokine TGF-β, est capable d'inhiber la formation des TH17 tumorigéniques.

Les risques de l’immunothérapie prolongée mieux évalués

« Cette étude peut interroger les cliniciens sur l'utilisation, sur une période longue des immunothérapies chez des patients atteints de cancer, un traitement qui vise à stimuler les lymphocytes », souligne Julien Marie.

En effet, si ces thérapies ont transformé la prise en charge en oncologie, elles sont aussi connues pour entraîner de l’inflammation chronique intestinale. Il est donc important de s'interroger, pour un patient donné, sur les risques que l'immunothérapie s'accompagne de l'émergence de lymphocytes TH17 tumorigéniques qui pourraient à terme donner lieu au développement d'un autre cancer. Par ailleurs, cette étude pose les bases pour le développement de nouvelles thérapies préventives du cancer en bloquant l'apparition du sous-type de TH17 mis en cause par les scientifiques dans ce travail.

[1] Ont également participé à ces travaux des scientifiques de l'Institut de génétique moléculaire de Montpellier (CNRS/Université de Montpellier).

[2] Julien Marie est lauréat du Prix Bettencourt Coups d'élan pour la recherche française. Créé par la fondation Bettencourt Schueller en 2000, ce prix a récompensé 78 laboratoires français et plus de 900 chercheurs jusqu'en 2021.

(Source: FuturaSciences.com)

Chinese scientists have harnessed one of the human body's fastest and strongest immune responses to develop a potential new weapon to fight cancer, according to a study published in Cell on Wednesday.

The research, led by scientists from Zhejiang University and the First Hospital of China Medical University, focused on mast cells, which are immune cells known for triggering allergic symptoms such as hives and sneezing. Mast cells are loaded with tiny packets of inflammatory molecules and can react within seconds when triggered.

Gu Zhen, a professor at the School of Pharmacy at Zhejiang University and one of the leaders of the research team, said that the overactive immune response inspired the team to explore whether inducing allergic-type reactions in tumors could help overcome tumor immunosuppression.

Instead of allowing mast cells to respond to allergens, the team reprogrammed them using IgE antibodies that recognize proteins found on tumor cells. When these customized mast cells are injected into the bloodstream, they travel to tumors and unleash sudden bursts of inflammation upon encountering their specific cancer target.

The allergy-like reaction inside the tumor helps activate the immune system and turn quiet, hard-to-treat tumors -- "cold" tumors, which typically evade immune detection -- into "hot" ones that the immune cells can recognize and attack.

The researchers also found that mast cells can serve as living carriers for oncolytic viruses -- viruses that selectively infect and kill cancer cells.

By hiding these viruses inside vesicles of mast cells, the team protected them from being destroyed in the bloodstream. Once the mast cells reached a tumor and became activated, the viruses were released.
In mouse melanoma, breast cancer and lung metastasis test subjects, the approach drew more cancer-killing T cells into the tumor and inhibited tumor growth, according to the study.

This strategy also worked in patient-derived tumor models. Human mast cells equipped with IgE antibodies targeting common tumor marker HER2 and loaded with an oncolytic virus triggered strong T-cell responses and notable tumor suppression, the study found.

"This opens up possibilities for precision therapy in the future," Gu said, adding that matching IgE antibodies to a patient's own cancer markers could rapidly create a personalized therapy.

Beyond oncolytic viruses, mast cells can carry a wide range of therapies, including drugs, proteins, antibodies, and even nanomedicines, and then release them only when they encounter the tumor. The researchers said that the platform could one day support multiple treatment modes within a single cell-based therapy.

The team plans to establish a workflow for the selection of patient-specific IgE antibodies, scale up manufacturing of therapeutic mast cells, and explore combinations with existing cancer immunotherapies, aiming to bring their approach to clinical application as soon as possible, Gu said.

(Source : News.cn)

Retinol is the active form of vitamin A that the eye uses as a chemical building block for seeing. In the retina, retinol is converted into a related molecule called 11-cis-retinal, which fits into light-sensing proteins (opsins) to form rhodopsin and other visual pigments. When light hits those pigments they change shape and trigger the photoreceptor cells to send an electrical signal to the brain — that chain of events is the molecular basis of vision, especially in low light. (ods.od.nih.gov)

This conversion and recycling of retinoids is called the “visual cycle.” After photoreceptors absorb light, the retinal part of the pigment becomes all-trans-retinal and is then reduced to all-trans-retinol; that retinol is shuttled to the retinal pigment epithelium (RPE) and enzymatically converted back to 11-cis-retinal so it can be reused. Specialized carrier proteins (for example interphotoreceptor retinoid-binding protein and retinol-binding protein in the blood) control retinol transport and delivery to the eye. Interruptions anywhere in this cycle — from low dietary supply to problems with transport or enzymes — reduce the eye’s ability to make the light-sensitive chromophore and weaken visual function. (Nature)

The practical effects of inadequate retinol are well documented. The earliest and most noticeable sign is difficulty seeing in dim light (night or twilight blindness). With progressing deficiency the surface tissues of the eye (the conjunctiva and cornea) become dry and damaged — a condition called xerophthalmia — and, in severe cases, this can lead to corneal ulceration and permanent blindness. Public-health programs that prevent or treat vitamin A deficiency reduce these eye problems and the blindness that can follow. (Organisation mondiale de la santé)

For people who are actually deficient in vitamin A, oral retinol (or appropriate vitamin A supplementation) commonly produces real, measurable benefits: night-vision improves, conjunctival and corneal health recovers, and further progression to severe eye disease is prevented. In contrast, adding extra retinol to someone who already has adequate vitamin A does not meaningfully improve visual acuity or night vision and can be harmful if taken in excess. (Organisation mondiale de la santé)

There are safety and clinical points to keep in mind. Vitamin A is fat-soluble and stored in the liver, so chronic high intake of preformed vitamin A (retinol) can cause toxicity; very high doses are teratogenic and must be avoided in pregnancy. People with disorders that impair fat absorption (for example some intestinal diseases) or those on certain medications may become deficient and benefit from medical evaluation and guided supplementation. Because the benefits and risks depend on individual status, testing and medical advice are appropriate if someone suspects a deficiency. (Mayo Clinic)

In short: retinol is essential for the chemical steps that let photoreceptors detect light and for keeping the eye surface healthy. Restoring normal vitamin A levels reliably improves night vision and ocular surface health in deficient people, but it is not a “vision enhancer” for those who already have sufficient vitamin A, and inappropriate dosing carries real risks. (ods.od.nih.gov)

(Source : ChatGPT)

Psoriasis is a disorder in which the skin’s normal cycle of cell growth and maturation is thrown off: skin cells called keratinocytes divide too quickly and fail to mature normally, producing thick, scaly plaques. Retinoids—drugs chemically related to vitamin A—can help correct those core problems because they change how skin cells read their genes. When retinoids enter keratinocytes they bind to nuclear receptor proteins (retinoic acid receptors and retinoid X receptors). Those receptors act like switches for groups of genes that control cell division, the program of cell maturation, and inflammatory signals. By altering gene activity, retinoids reduce excessive keratinocyte proliferation and push cells toward a more normal pattern of differentiation, which tends to thin plaques and reduce scaling. (Tandfonline)

In addition to slowing down over-fast cell division and helping cells mature correctly, retinoids also influence inflammatory and vascular components of psoriatic plaques. Some retinoids lower the expression of molecules that recruit inflammatory cells and promote new small blood-vessel growth in the skin. Those anti-inflammatory and anti-angiogenic effects work together with the direct effects on keratinocytes to produce clinical improvement. (JAAD)

Clinically, these mechanisms translate into effective treatments in specific forms and uses. Topical tazarotene, a receptor-selective retinoid, has been shown in controlled trials to reduce plaque thickness and scaling and is an approved topical option for plaque psoriasis; it is often combined with topical corticosteroids or with phototherapy to increase benefit and reduce irritation. Oral retinoids such as acitretin are used systemically for more severe or pustular forms of psoriasis and can normalize the abnormal keratinocyte behavior across large body areas; they are frequently used together with phototherapy or other systemic agents to improve outcomes. (ScienceDirect)

Important practical points follow from this mechanism. Because retinoids act by changing gene expression, their benefits are generally gradual (over weeks) rather than instantaneous, and sustained improvement often requires continued or repeated treatment. Also, topical retinoids commonly irritate the skin (dryness, redness, peeling) at first; that irritation can be managed by starting with lower frequency or combining with a mild steroid or emollient. Systemic retinoids carry more significant risks—most notably strong teratogenicity (they can cause major birth defects) and other dose-related adverse effects—so they require strict pregnancy prevention measures and medical monitoring when used. For these reasons a dermatologist typically tailors which retinoid (topical vs systemic), what dose, and which combinations are appropriate for an individual patient. (PubMed)

In short, retinoids help in psoriasis because they correct the two central cellular problems—too much keratinocyte proliferation and abnormal differentiation—while also reducing some inflammatory signals. Their actions are well matched to the biology of psoriatic plaques, which explains why dermatologists use receptor-selective topical retinoids for localized disease and systemic retinoids for more severe presentations, always balancing benefit against irritation and systemic risks. (JAAD)

How Retinoids Normalize Psoriatic Skin Despite Increasing Cell Shedding

Short answer first: not necessarily — retinoids can ultimately improve psoriasis because they change the way keratinocytes behave, even though they also speed surface cell turnover; that initial increase in shedding can look worse at first but the long-term effect is a normalization of growth and maturation that reduces thick scaling. (PubMed)

To explain clearly: retinoids (the family that includes retinol, tretinoin, tazarotene, and systemic drugs like acitretin) act inside skin cells by binding to nuclear receptors that control gene expression. Those receptors turn on and off sets of genes that govern how quickly keratinocytes divide and how they mature into the outer layers of the skin. In psoriatic skin the program is disturbed: keratinocytes divide too fast and don’t undergo the normal maturation steps. Retinoids shift the cells back toward a more normal pattern — they can slow the pathological proliferation, encourage correct differentiation, and reduce some inflammatory signals that feed the plaque. Those are precisely the actions dermatologists exploit when they use receptor-selective topical retinoids (for example tazarotene) or oral retinoids (for example acitretin) to treat psoriasis. (PubMed)

Why speeding turnover doesn’t simply make psoriasis worse: “turnover” is not a single thing. Retinoids do increase the rate at which surface cells are replaced, but they also change how those cells mature and how tightly the outer cells stick together. In healthy, well-regulated skin faster, orderly turnover can improve texture; in psoriatic skin, retinoids reduce abnormal cell-to-cell cohesion and help the abnormal, immature cells complete their differentiation program so they are shed more normally rather than accumulating as a thick, compact scale. Because of this improved maturation and desquamation, plaques thin and scaling decreases over weeks even if visible flaking is more noticeable at first. The time course matters: benefits usually appear over weeks while the early “adjustment” can temporarily look worse. (MDPI)

Practical caveats: over-the-counter retinol is weaker and converts slowly to active retinoic acid, so it is generally less useful for treating established psoriasis than prescription retinoids such as topical tazarotene or systemic acitretin, which are chosen because they have clearer antiproliferative and differentiation-normalizing effects. Retinoids commonly irritate skin (redness, dryness, peeling) and that irritation can itself provoke inflammation or a perceived flare, so clinicians often introduce them gradually, combine them with topical corticosteroids or emollients to limit irritation, and supervise systemic use because of important risks (for example teratogenicity with acitretin). For those reasons retinoid treatment for psoriasis is best done under a dermatologist’s guidance. (PubMed)

In short: the conversion of topical retinol to retinoic acid and the resulting increase in cell turnover does not automatically worsen psoriasis; by redirecting gene programs toward normal differentiation and reducing pathological proliferation, retinoids can reduce plaque thickness and scaling over time — provided they are used at the right strength and with strategies to control early irritation. (PubMed)

(Source : ChatGPT)

Quote : " Methylene blue has an oxidized phenothiazine ring system, as opposed to many other phenothiazine drugs which have reduced ring systems. This difference has profound effects on action and activity, as it increases the chemical structure’s angle and gives the ring system a positive charge. This allows methylene blue to interact differently with membranes and intracellular structures. For example, staining with methylene blue can be used to show membrane damage. " [x]

The passage you quoted is describing, in short form, how a specific chemical feature of methylene blue — the way its central ring system is chemically “oxidized” and therefore carries a positive charge and a particular three-dimensional shape — changes the way the molecule behaves around cells and cell parts. Here’s a clear, plain-language unpacking of each idea and what it means in practice.

A phenothiazine ring is a three-ring chemical scaffold found in several kinds of molecules. You can think of it as a flat set of connected rings made from carbon and a couple of heteroatoms (sulfur and nitrogen). When chemists say a ring system is “oxidized” they mean that, at one or more positions, electrons have been removed or the atoms carry a formal positive charge compared with a “reduced” version. For methylene blue that oxidized form is stable and the molecule exists as a positively charged ion. That positive charge is a simple but powerful change: many biological surfaces and molecules — cell membranes, nucleic acids, some proteins — carry negative charges, so a positively charged dye is attracted to and binds those negatively charged sites by electrostatic forces.

The text’s comment about the ring system’s “angle” refers to the molecule’s three-dimensional shape. Chemical oxidation can change how flat or bent the ring system is; in methylene blue the structure is not perfectly flat and the positive charge is distributed over the ring system. A change in shape matters because molecules interact physically with membranes and proteins much like puzzle pieces: a flatter molecule might slide between stacked flat structures, while a more bent or angled molecule will sit differently against a curved membrane surface or fit into grooves of proteins in a different way. So, the altered angle plus the positive charge together change where and how strongly methylene blue sticks to membranes and intracellular structures.

Those two properties — positive charge and a particular 3D shape — explain two practical behaviors of methylene blue. First, because it is cationic (positively charged) and somewhat lipophilic, it tends to accumulate in sites with a negative electrical potential, especially mitochondria (the cell’s energy organelles) which have a strongly negative inner membrane potential. That accumulation helps explain why methylene blue can affect cellular energy chemistry and appear in certain parts of the cell under the microscope. Second, as a basic (cationic) dye, methylene blue binds readily to negatively charged cellular material. In microscopy, this is why it stains some tissues or cell compartments: if the dye can reach and bind internal components they will appear colored.

When the sentence says “staining with methylene blue can be used to show membrane damage,” it is referring to a common laboratory idea: intact cell membranes are selective barriers, and a dye that cannot normally cross an intact membrane will be excluded from the cell interior. If the membrane is damaged, the dye can enter and stain inner structures (or stain in a different pattern). That change in staining pattern — for example, cells that suddenly take up blue dye while healthy cells do not — is a practical indicator that membranes have been compromised. In other words, the dye’s entry into parts of the cell it normally can’t reach is used as a sign that the membrane barrier failed.

It is important, however, to be cautious about interpreting such staining. Staining patterns depend on many factors: the exact chemical form of the dye (it can be reduced to a colorless form in some conditions), the concentration used, how long cells are exposed, and the experimental conditions (pH, temperature, presence of proteins that bind the dye). A positive stain is an indicator, not definitive proof, of membrane damage: good experimental practice includes controls (untreated cells, known-damage controls) and complementary tests to confirm that membranes are truly compromised rather than simply more permeable under the test conditions or chemically altered in ways that change dye binding.

In short, the statement is making three linked points that are chemically sensible in broad terms: methylene blue’s oxidized, positively charged phenothiazine core gives it a particular three-dimensional shape and charge distribution; those features change how it associates with membranes and intracellular structures; and because of that, changes in where the dye ends up (how cells stain) can be used as a practical indicator of membrane integrity. The real-world interpretation of staining, though, requires attention to experimental detail and corroborating evidence.

(Source : ChatGPT)

Methylene blue is a small synthetic dye with a long medical history that also behaves as a biologically active drug. Chemically it is a redox-active thiazine dye that can accept and donate electrons; in cells this property lets it act as an alternate electron carrier and antioxidant, and it also influences some enzyme systems. Because of those biochemical actions, methylene blue has both well-established emergency uses in medicine and a growing—but still experimental—literature exploring effects on cellular energy and brain function. (NCBI)

The most important and widely accepted clinical use of methylene blue is as an antidote for methemoglobinemia, a condition in which the iron in hemoglobin is oxidized and cannot carry oxygen normally. Given intravenously at carefully controlled doses, methylene blue helps reduce methemoglobin back to functional hemoglobin and usually reverses the dangerous oxygen-carrying problem within minutes to hours; this effect is the reason the compound remains a standard emergency treatment. (NCBI)

Beyond its emergency role, methylene blue concentrates in mitochondria and can act as a reversible redox mediator: it can accept electrons from NADH and donate them downstream in the electron transport chain. In cell and animal studies this action can lower harmful reactive oxygen species, support ATP production when parts of the chain are compromised, and protect neurons from some forms of stress. Those biochemical properties have driven research into possible neuroprotective and cognitive uses—examples include small clinical trials and ongoing studies in age-related cognitive decline and Alzheimer’s disease—but the human evidence is preliminary and not yet definitive. (PMC)

Methylene blue is not without important risks. It is a reversible monoamine oxidase inhibitor (MAOI) and can trigger serious serotonin toxicity if given to a person taking serotonergic psychiatric medications (for example SSRIs or SNRIs); regulatory agencies have issued safety communications advising caution or avoidance of methylene blue in that situation. The drug can also cause dose-related adverse effects (for example nausea, headache, confusion, and circulatory or respiratory symptoms) and produces an unmistakable blue or green discoloration of urine and sometimes skin or mucous membranes. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency are at particular risk of oxidative hemolysis when exposed to methylene blue, so clinicians take care before using it in people with known or suspected G6PD deficiency. For all these reasons methylene blue is normally given only under medical supervision, in controlled doses and with monitoring. (U.S. Food and Drug Administration)

In summary, methylene blue is a medically useful redox dye: its proven, lifesaving role is treating methemoglobinemia, and its ability to modulate mitochondrial electron flow and oxidative stress has prompted research into neuroprotection and cognitive applications. Those experimental uses are promising at a mechanistic level but remain investigational, and the drug’s interaction profile and risks (especially serotonin toxicity and hemolysis in G6PD deficiency) mean it must be used with medical oversight rather than as an over-the-counter “wellness” supplement. (NCBI)

(Source : ChatGPT)

Spermidine’s story begins long before modern biochemistry gave it a role in cell biology. In 1678 the microscopist Antonie van Leeuwenhoek described curious crystalline material in human semen; those early observations marked the first recorded encounter with the family of molecules that would later be called polyamines. Over the next century and into the 19th century investigators occasionally rediscovered similar “sperm-crystals,” and by the late 1800s chemists had begun to isolate and name related bases such as “spermin” (an old spelling for what became spermine). These scattered natural-history observations established the empirical fact that unusual, basic organic compounds were present in reproductive fluids and some tissues. (PubMed)

The chemical characterization of spermidine itself belongs to the early 20th century. Work by H. W. Dudley together with O. Rosenheim and W. W. Starling culminated in a 1927 Biochemical Journal paper titled “The Constitution and Synthesis of Spermidine,” which isolated the triamine from animal tissues and described its chemical structure and synthesis. That paper marks the moment spermidine moved from a curious extractable base into a defined chemical entity that chemists and biochemists could study experimentally. (PubMed)

During the mid-20th century researchers shifted from simple isolation and naming to understanding how polyamines are made in living cells. Seminal work by Herbert and Celia Tabor in the 1950s used isotopic tracers to show that spermidine and spermine are biosynthesized from the diamine putrescine and from methionine-derived aminopropyl groups; that 1958 work clarified the basic biosynthetic pathway and established enzymes and precursors that laboratories would study for decades. Identification of the key enzyme ornithine decarboxylase (ODC) as the rate-limiting step in polyamine production also emerged from this era and set the stage for biochemical and pharmacological manipulation of polyamine levels. (PubMed)

In the 1970s another major discovery linked spermidine chemically to protein function. In 1971 Shiba and colleagues isolated and described a novel amino acid, hypusine, from bovine brain and later showed that this unusual residue is formed by transfer of an aminobutyl group derived from spermidine onto a specific lysine in the protein now known as eukaryotic initiation factor 5A (eIF5A). The finding that a single, highly conserved translation factor carries a modification that depends directly on spermidine made clear that this small polyamine was not merely a metabolic curiosity but a specific biochemical donor with essential roles in protein synthesis and cell proliferation. (PubMed)

Through the latter decades of the 20th century, polyamine research broadened into physiology and medicine. Investigators observed links between polyamine metabolism and cell growth, and clinicians and biochemists explored whether measurement or manipulation of polyamines could have diagnostic or therapeutic value; for example, elevated urinary polyamines in cancer patients attracted oncological interest in the 1970s and beyond. Pharmacological approaches to modulate polyamine synthesis — most famously the development of α-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC — arose from the idea that limiting polyamine availability might slow uncontrolled cell proliferation. (PubMed)

A new wave of attention arrived in the 21st century when mechanisms relevant to aging and cellular quality control were linked to spermidine. A landmark 2009 study led by Tobias Eisenberg and colleagues reported that spermidine administration extended lifespan in yeast, worms and flies and protected cultured human immune cells from age-related decline, actions closely tied to stimulation of autophagy, the cell’s intracellular recycling pathway. That work reframed spermidine as a candidate “caloric-restriction mimetic” and sparked intense interest in its potential to influence health span. Subsequent animal studies, including mouse experiments showing cardioprotective effects and improved cardiac function with dietary spermidine, reinforced the idea that its cellular actions could have tissue-level benefits. (PubMed)

Human epidemiology has begun to follow these experimental leads. A prospective, population-based study published in 2018 reported that higher dietary spermidine intake was associated with lower all-cause mortality, lending tentative support to the translational relevance of the laboratory findings while underscoring the need for controlled clinical trials to test causality and safety in people. At the same time, researchers remain cautious: spermidine acts on fundamental cellular processes, so context (age, disease state, cancer risk, dose and duration) matters for interpreting potential benefits and risks. (PubMed)

Summarizing the arc: casual seventeenth-century observations of “sperm crystals” evolved into chemical isolation and structural definition of spermine and spermidine in the early 20th century (Dudley and colleagues, 1920s); mid-century tracer work and enzyme biochemistry (Tabor and others, 1950s–60s) established biosynthetic pathways; discovery of hypusine in 1971 linked spermidine chemically to a unique and essential protein modification; and modern molecular and animal studies in the 2000s–2010s have proposed autophagy, mitochondrial support and other mechanisms that may explain spermidine’s beneficial actions in aging and cardiovascular models. Each phase—observation, chemical definition, biosynthetic and enzymatic mapping, mechanistic molecular biology, and translational animal/human work—has contributed a layer to the scientific story of this small but biologically influential molecule. (PubMed)

(Source : ChatGPT)

Mitochondria are the cell’s energy factories: they generate most of the ATP that cells use to perform work, and they also coordinate important signals for metabolism and cell survival. Because mitochondria wear out, become damaged, or produce harmful reactive oxygen species (ROS) as we age or under stress, cells rely on a set of quality-control mechanisms to keep mitochondria healthy. Spermidine helps mitochondria by acting at several complementary points of that quality-control system — it promotes the removal of damaged mitochondria, supports the production of mitochondrial proteins, and encourages the renewal of the mitochondrial pool — and these actions together improve mitochondrial function in many experimental settings.

One major way spermidine improves mitochondrial health is by activating autophagy, the cellular recycling pathway. Spermidine inhibits the acetyltransferase EP300, which normally represses cytoplasmic autophagy machinery; by reducing EP300 activity, spermidine lowers acetylation of key autophagy proteins and thereby facilitates the formation of autophagosomes that engulf damaged cellular components. When this autophagy response includes selective removal of defective mitochondria (a process called mitophagy), the net result is a cleaner, more efficient mitochondrial population. This EP300-related activation of autophagy is a central mechanism by which spermidine has been shown to benefit cells in many laboratory studies. (PubMed)

Spermidine also affects mitochondrial function through its role in protein synthesis. It is used in the biochemical modification called hypusination of the translation factor eIF5A; hypusinated eIF5A is required for efficient translation of certain proteins, including some that are important for mitochondrial respiration and maintenance. By supporting eIF5A hypusination, spermidine helps restore or maintain the synthesis of mitochondrial proteins that are needed for normal electron transport and energy production, which in turn improves mitochondrial respiration in disease models. Evidence that restoring eIF5A hypusination can rescue mitochondrial protein synthesis and function in models of metabolic disease highlights this as a distinct, translation-linked route through which spermidine benefits mitochondria. (Cell)

Beyond general autophagy and translational support, spermidine can trigger specific signaling cascades that promote mitophagy. Experimental work has shown that spermidine can activate the ATM kinase, which then helps initiate the PINK1/Parkin pathway — a well-characterized mitophagy route that tags damaged mitochondria for degradation. By engaging PINK1/Parkin, spermidine promotes selective clearance of dysfunctional mitochondria rather than indiscriminate removal of healthy ones, improving the overall health and efficiency of the mitochondrial network. (Nature)

Spermidine has also been linked to improved mitochondrial renewal and biogenesis through effects on metabolic regulators. Studies in heart and other tissues indicate spermidine can influence the SIRT1–PGC-1α axis, a pathway that stimulates mitochondrial biogenesis and antioxidant defenses. By supporting these regulators, spermidine not only removes bad mitochondria but also helps build new, functional ones, shifting the balance toward a more robust and better-performing mitochondrial population. This combined effect — enhanced clearance of damaged mitochondria plus stimulated biogenesis — is especially valuable for tissues with high energy demand. (PMC)

The functional consequences observed in experimental systems are consistent: spermidine treatment often improves measures of mitochondrial respiration, lowers markers of mitochondrial dysfunction, and reduces age-related accumulation of damaged mitochondria in model organisms. These mechanistic effects — autophagy/mitophagy induction, support for mitochondrial protein synthesis via eIF5A hypusination, and activation of biogenesis pathways — together explain why spermidine can make mitochondria “perform better” in cells and animals. Human data are more limited: observational studies and a growing but still small number of clinical investigations point toward benefits for cardiometabolic health and cellular bioenergetics, but large controlled trials are needed to confirm whether the mitochondrial effects seen in the lab translate into robust clinical outcomes. (PMC)

In plain terms: spermidine helps mitochondria by cleaning out the damaged ones (via autophagy and PINK1/Parkin mitophagy), helping cells make the mitochondrial proteins they need (via eIF5A hypusination), and encouraging the birth of new mitochondria (via SIRT1/PGC-1α and related signals). These coordinated actions reduce dysfunctional mitochondria and boost respiration, which is why spermidine is widely studied as a compound that supports cellular energy and resilience. Because much of the detailed mechanistic evidence comes from cell and animal work, the clinical relevance for humans is promising but not yet definitive. (PubMed)

(Source : ChatGPT)